Current Headlines

  1. Google’s Calico Enters R&D Partnership To Tackle Brain Disorders
    9/15/2014

    Google’s life sciences startup Calico announced that it has signed a research and development partnership to tackle neurodegenerative disorders caused by the deterioration and death of nerve cells.

  2. Genocea Kicks Off Phase 2 Trial For Pneumococcus Vaccine
    9/15/2014

    Clinical stage biopharmaceutical firm Genocea announced that it has started the Phase 2A trial for GEN-004, its universal vaccine candidate against pneumococcus.

  3. Burnet Scientists ID Proteins For Malaria Vaccines
    9/15/2014

    The Burnet Institute reported that several of its researchers have identified a group of proteins that has the potential to be the cornerstone of new diagnostics and vaccines against malaria.

  4. CDMO Patheon To Manufacture Novel Polymer For Relypsa
    9/15/2014

    Relypsa, Inc. announced in a press release that it has engaged Patheon, a contract development and manufacturing organization (CDMO), to produce patiromer, a novel polymer. The multi-year commercial manufacturing and supply agreement with Patheon is for the finished product manufacture of the agent to treat hyperkalemia. Relypsa plans to name Patheon as the manufacturer in its New Drug Application (NDA) to the Food and Drug Administration (FDA). Wilhelm Stahl, Ph.D., SVP of Pharmaceutical Operations at Relypsa, said, “Having multiple, well-respected and proven global pharmaceutical suppliers gives us confidence in meeting potential demand and providing a high quality product to patients."

  5. Experimental Stem Cell Treatment Cleared For First Human Trial
    9/12/2014

    Japanese researchers at the RIKEN Center for Developmental Biology (CDB) have prepared a potential treatment using stem cells to treat degenerative eye diseases, and they are set to begin testing the treatment on the first human patient very soon.

  6. MabVax Links Arms With MSK, Juno For Anti-Cancer Drugs
    9/12/2014

    Clinical stage biotech firm MabVax Therapeutics announced that it has entered into partnerships with Memorial Sloan Kettering Cancer Center (MSKCC) and Juno Therapeutics to develop novel anti-cancer therapeutics using MabVax’s antibody discovery platform.

  7. Genmab And Seattle Genetics Expand ADC Collaboration
    9/12/2014

    Biotech firms Genmab and Seattle Genetics announced a new antibody-drug conjugate collaboration to create an ADC that will target AXL, a prominent signaling molecule on multiple solid tumors that plays a key role in tumor development and growth. Over the course of the partnership, Genmab and Seattle Genetics will co-develop HuMax-AXL-ADC, an ADC that combines an AXL-targeting, high affinity human monoclonal antibody with Seattle Genetics’ cytotoxic drug.

  8. Altor, Shenzhen Beike Enter Immunotherapy Agreement In China
    9/12/2014

    Altor BioScience, a U.S. firm developing novel cancer immunotherapies, and Shenzhen Beike Biotechnology, a Chinese cell-based therapy firm, announced that the companies have signed into a license agreement for the development and commercialization of immunotherapy ALT-803 in China.

  9. NeuroVive, OnCore BioPharma Sign $150M Licensing Agreement For HBV Infection Treatment
    9/11/2014

    Sweden based NeuroVive Pharmaceutial has just entered into an exclusive worldwide licensing agreement with U.S. biotech company OnCore BioPharma for the development and commercialization of NeuroVive’s drug candidate NVP018 for chronic Hepatitis B Virus (HBV) infection.

  10. Potential Treatment Discovered For Autoimmune Diseases
    9/11/2014

    Researchers at the University of Bristol have made an important breakthrough that could lead to new treatments for debilitating autoimmune diseases; they have discovered a process to 'switch off' these diseases. This discovery points to the use of antigen-specific immunotherapy as a treatment for many autoimmune disorders, including multiple sclerosis (MS), type 1 diabetes, Graves' disease, and systemic lupus erythematosus (SLE).